Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic introduces Captivia delivery system in Canada
The Captivia delivery system features tip capture for enhanced control of the Valiant Thoracic Stent Graft during deployment and a hydrophilic coating applied to the graft cover to
The Captivia delivery system features tip capture for enhanced control of the Valiant Thoracic Stent Graft during deployment and a hydrophilic coating applied to the graft cover to
ApoB100 is the structural protein of Low Density Lipoprotein (LDL) particles that carry cholesterol. Silencing the activity of ApoB100 with miRNA or shRNA lowers plasma LDL-cholesterol by 60-80%
GPCRs, which mediate key physiological processes in the body, are one of the most valuable families of drug targets. Omeros has begun screening orphan GPCRs against its small-molecule
Nuvigil and Provigil are indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy. The goal
Obtaining the drug certificate is in continuation of Sinovac’s strategy to explore opportunities to export its vaccines manufactured in mainland China to targeted areas and countries worldwide. Sinovac
Based on the first contract with the Beijing CDC, Sinovac is expected to supply 375,000 doses of seasonal influenza vaccine, Anflu, valued at $1.3m. Sinovac chairman, president and
Fipamezole is being prepared for Phase III development for the treatment of Dyskinesia in Parkinson’s Disease. Previously, Santhera has entered into a collaboration and licensing agreement with Biovail
Menveo showed immunogenicity in infants potentially offering protection against four major serogroups of meningococcal disease. Menveo was generally well tolerated when given either alone or co-administered with other
Dr Reddy’s Laboratories has posted a net income of $64m for the Q2 FY11, or $0.4 per diluted share, compared to net income of $48.92m, or $0.3 per
NeuroVive will fund the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly. to-BBB CSO